Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Ernst-Wilhelm Radue, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Richard A Rudick, Fred D Lublin, Bianca Weinstock-Guttman, Daniel R Wynn, Elizabeth Fisher, Athina Papadopoulou, Frances Lynn, Michael A Panzara, Alfred W Sandrock, SENTINEL Investigators, Per Soelberg Sørensen, Morten Bjørn Blinkenberg

50 Citations (Scopus)

Abstract

The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p
Original languageEnglish
JournalJournal of the Neurological Sciences
Volume292
Issue number1-2
Pages (from-to)28-35
Number of pages8
DOIs
Publication statusPublished - 15 May 2010

Fingerprint

Dive into the research topics of 'Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis'. Together they form a unique fingerprint.

Cite this